AHA - American Hospital Association
01/31/2025 | News release | Distributed by Public on 01/31/2025 13:27
FDA approves first in class non opioid painkiller
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to severe acute pain in adults. The drug is manufactured by Vertex Pharmaceuticals. According to the FDA, Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system before pain signals reach the brain.
AHA - American Hospital Association published this content on January 31, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on January 31, 2025 at 19:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]